Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

October 12, 2017: By Joan McKenna
Notal Vision's ForeseeHome monitoring device

Notal Vision’s ForeseeHome monitoring device

Notal Vision announced Oct. 5 that patients have used its ForeseeHome monitoring device 3 million times.

It is the first US FDA-cleared home monitoring system for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD.

The self-administered test is designed to detect wet AMD at an earlier stage, allowing doctors to treat patients sooner in disease progression and possibly prevent loss of sight.

The system received US clearance in December 2009 and was used in clinical research before being commercially launched in October 2013. It gained Medicare reimbursement in 2016.

In 2010, the National Eye Institute began using the ForeseeHome in a secondary study to AREDS2 in 1,500 patients. Ninety percent of patients who used the device twice weekly and progressed to wet AMD maintained 20/40 or better vision, compared with 62 percent of patients whose diagnosis was during a routine eye exam or visit triggered by symptoms.

Notal Vision is headquartered in Tel Aviv, Israel, with a US office and distribution center in Virginia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022